Poolbeg Pharma's shares rose 9% following positive feedback from a pre-investigational new drug meeting with the FDA regarding its lead cancer therapy, POLB 001. The FDA's alignment reduces risks in the drug's development and strengthens Poolbeg's position in partnership talks by increasing confidence in the approval pathway. POLB 001 aims to prevent cytokine release syndrome, a serious side effect of cancer immunotherapy, with clinical trial data expected this summer. The drug targets a multi-billion-dollar market, and Poolbeg also plans to start a study on an oral obesity treatment later in 2026.
The US government, under the Trump administration, is negotiating to take equity stakes in domestic drone manufacturers to accelerate production, reduce costs, and lessen dependence on Chinese drone components. This move supports the 'Drone Dominance...
Bank of N.T. Butterfield announced it will acquire CIBC's 91.7% stake in CIBC Caribbean Bank Limited for approximately $1.8 billion, combining cash and shares. This acquisition aims to create a larger banking and wealth management platform in the Car...
Peec AI, an AI search analytics platform, surpassed $10 million in annual recurring revenue just 16 months after launch, doubling revenue in the last five months. The company is expanding rapidly, opening its first US office in New York to meet growi...
The National Crime Prevention Council (NCPC) has called on lawmakers to reject the House's Kids Internet and Digital Safety Act (H.R. 7757), criticizing it as insufficient for protecting children online. NCPC argues the bill weakens state powers and ...
Fannie Mae has started marketing a sale of approximately 2,333 reperforming loans with an unpaid principal balance of about $565 million. These loans were previously delinquent but have since become current. Buyers must offer loss mitigation options,...
